Principles of decisions making at NICE

Similar documents
Making Economic Evaluation Fit for Purpose to Guide Resource Allocation Decisions

Bringing Together Health Economics and Clinical Research

Value Based Health Care in the UK: NICE, VBP and the Cost-effectiveness Threshold. Eldon Spackman, MA, PhD

Evidence based assessment of the value of innovation: pricing solutions and prospects

NICE Guidelines for HTA Issues of Controversy

Pharmacoeconomics: from Policy to Science. Olivia Wu, PhD Health Economics and Health Technology Assessment

Shining Steel or Illegitimate Science?

Professor Karl Claxton, Centre for Health Economics, University of York

QALYs and the QALY problem in PC. 1. Idea of the QALY 2. QALY problem in Palliative Care

CAUSES FOR CONCERN: IS NICE FAILING TO UPHOLD ITS RESPONSIBILITIES TO ALL NHS PATIENTS?

National Primary Care Research and Development Centre and University of York Health Economics Consortium (NICE External Contractor)

Economic Evaluation. Introduction to Economic Evaluation

Methods for the Estimation of the NICE Cost Effectiveness Threshold

Methods for the Estimation of the NICE Cost Effectiveness Threshold

The cost of cancer treatment

Cost-effectiveness of brief intervention and referral for smoking cessation

How to evaluate the economic impact of interventions I: introduction and costing analyses

Minimizing Cost per Quality-Adjusted Life Year Gained?

Ethics in the context of medicine. How to develop professional values in dealing with economic issues. Isabelle Durand-Zaleski (Paris, France)

Health Economic Assessment: Cost-Effectiveness Thresholds and Other Decision Criteria

Setting The setting was a hospital. The economic study was conducted in the USA.

Setting The setting was the community. The economic study was carried out in the USA.

Economic evaluations of health technologies: insights into the measurement and valuation of benefits

Type of intervention Secondary prevention and treatment; Other (medication coverage policy design).

Subgroups and Heterogeneity in Cost-Effectiveness Analysis

Health Economics Research Centre. The cost-effectiveness of policies to reduce radon-induced lung cancer

Cost-effectiveness of osimertinib (Tagrisso )

Discussion Papers in Economics

The Economics of Obesity

Health Services Research and Health Economics. Paul McCrone Institute of Psychiatry, King s College London

Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)

Response to HIV LOGISTICAL AND OTHER PERSPECTIVES

Using whole disease models to inform resource allocation decisions. Paul Tappenden Senior Research Fellow May 2010

The cost-utility of screening for depression in primary care Valenstein M, Vijan S, Zeber J E, Boehm K, Buttar A

Back to the future: should we live in a post-qaly world?

National Priorities of Oriented Research, Experimental Development and Innovation in the Czech Republic. March 14th, 2013 PACITA conference, Prague

Panel Value Frameworks for Cancer Therapies: Are they Useful in the Context of Canadian Health Technology Assessments and Reimbursement Decisions?

An Introduction to Costeffectiveness

Introduction to Cost-Effectiveness Analysis

The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden Bolin K, Lindgren B, Willers S

ColonCancerCheck (CCC): Modelling FOBT screening in Ontario for colorectal cancer (CRC) using the Cancer Risk Management Model (CRMM)

ECONOMIC ANALYSIS TO SUPPORT NHS IMPLEMENTATION OF HEPATITIS C DRUGS: SCOPING STUDY

Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis Bayoumi A M, Redelmeier D A

EXECUTIVE SUMMARY 9. Executive Summary

Cost-Effectiveness and Value of Further Research of Treatment Strategies for Cardiovascular Disease

An economic analysis of sumatriptan for acute migraine Ilersich L

NICE decisions on health care provisions in England

Setting The setting was primary care. The economic study was carried out in Brazil, France, Germany and Italy.

Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma Brown R, Turk F, Dale P, Bousquet J

Health technology The use of the antihypertensive drug losartan for the prevention of stroke.

Health Technology Assessment and the Demands of the Fourth Hurdle Experiences from TLV in Sweden

An exploration of the cost-effectiveness of interventions to reduce. differences in the uptake of childhood immunisations in the UK using

Assessing Cost Effectiveness

Using pilot economic models to support grant applications for clinical trials:

A CASE STUDY OF VALUE OF INFORMATION

What is a Defendable Estimate of 0 Dementia Prevalence and Monetary Costs?

Sampling Uncertainty / Sample Size for Cost-Effectiveness Analysis

Economic Analyses in Clinical Trials

Is hospitalization after TIA cost-effective on the basis of treatment with tpa? Nguyen Huynh M N, Johnston S C

Using Health Economics to Inform the Development of Medical Devices. Matthew Allsop MATCH / BITECIC

Genomic Health, Inc. Oncotype DX Colon Cancer Assay Clinical Compendium March 30, 2012

Pap plus HPV every 3 years with screening stopped at 65, 75 and 100 years; Pap plus HPV every 2 years with screening stopped at 65, 75 and 100 years.

Putting NICE guidance into practice. Resource impact report: Hearing loss in adults: assessment and management (NG98)

Setting The setting was primary care. The economic study was conducted in the UK.

Past Imperfect, Present Tense, Future Conditional: Where next for value frameworks?

Herbert A. Simon Professor, Department of Philosophy, University of Wisconsin-Madison, USA

Health technology Sumatriptan therapy was compared with nontriptan medications in the treatment of acute migraine.

Health technology The study compared three strategies for diagnosing and treating obstructive sleep apnoea syndrome (OSAS).

2/20/2012. New Technology #1. The Horizon of New Health Technologies. Introduction to Economic Evaluation

Pertussis in adolescents and adults: should we vaccinate Lee G M, LeBaron C, Murphy T V, Lett S, Schauer S, Lieu T A

Project Team. David Lewis Leela Barham

UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator

Can you bring these to the attention of the committee when it meets. I hope to be there, and will gladly talk the committee trough them.

Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? Konski A, Speier W, Hanlon A, Beck J R, Pollack A

Access to newly licensed medicines. Scottish Medicines Consortium

Scaling up in Gender Analysis Workshop

How to evaluate the economic impact of influenza II: Methods and cost-effectiveness

Health economics of personalized medicine Winter School Clinical and Genetic Epidemiology Strategies to Drive Personalized Medicine

pan-canadian Oncology Drug Review Final Economic Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013

Review and consensus of cost effectiveness methods

Impact of health behaviours and health interventions on demand for and cost of NHS services in the North of Scotland (including Tayside)

Technology appraisal guidance Published: 22 September 2010 nice.org.uk/guidance/ta200

The long-term cost-effectiveness of bariatric surgery for the treatment of severe obesity: a cost utility analysis from a societal perspective

Cost-effectiveness of sebelipase alfa (Kanuma ) for the treatment of lysosomal acid lipase (LAL) deficiency infantile paediatric adult

Folland et al Chapter 4

Basic Economic Analysis. David Epstein, Centre for Health Economics, York

Breastfeeding support, designed to encourage greater initiation and duration, can take

4/22/16. Presentation Outline. Introduction. Stakeholder Conflict Management Matt Smith Introduction

Setting The setting was primary care. The economic study was carried out in the UK.

How cost-effective is screening for abdominal aortic aneurysms? Kim L G, Thompson S G, Briggs A H, Buxton M J, Campbell H E

A Primer on Health Economics & Integrating Findings from Clinical Trials into Health Technology Assessments and Decision Making

pan-canadian Oncology Drug Review Final Economic Guidance Report Osimertinib (Tagrisso) for Non-Small Cell Lung Cancer January 4, 2019

Nonpharmacologic Interventions for Treatment-Resistant Depression. Public Meeting December 9, 2011

Scottish Medicines Consortium

Cost effectiveness of early treatment with oral aciclovir in adult chickenpox Smith K J, Roberts M S

The cost-effectiveness of interventions in primary care a health economic perspective for decision-making. Miika Linna, Aalto University/HEMA

Making Value Based Pricing A Reality: Issue Panel

1. Comparative effectiveness of liraglutide

A Scottish adaptation of the Sheffield Alcohol Policy Model

Estimated number of people with hypertension. Significantly higher than the. Proportion. diagnosed with. hypertension

Transcription:

Principles of decisions making at NICE Karl Claxton Simon Walker Stephen Palmer Mark Sculpher Centre for Health Economics University of York, UK CHE/OHE Workshop, What perspective should be used in health care decisions? June 2010

Outline International context What the literature gives us Framework for NICE decision making Simple world: all costs fall on NHS More complex world: some effects outside NHS Considerations in selecting an appropriate perspective

What do we learn from international comparison? Payer Societal Both Not stated 13 (50%) 6 (23%) 6 (23%) 1 (4%) Acknowledgements: Marco Barbieri

Absence of clear rationale for selected perspective 50% of guidelines offer no rationale for their preferred perspective There is broad consensus nationally and internationally that the societal perspective is the most appropriate choice. (Netherlands) The perspective chosen should fit the needs of the target audience. (Canada) 27% (7/26) make reference to a budget constraint

Does the theoretical literature help us? Normative foundations of economic evaluation two broad paradigms Neo-classical welfare economics ( Welfarism ) Prescriptive framework for social choice Application in terms of cost benefit analysis Little consideration of budget constraints and consequent opportunity costs Non-Welfarist approaches Other outcomes can be considered other than just preferences Less prescriptive legitimacy comes from political and administrative system

A simple world: NHS budget constraint and health maximisation New technologies -Health gain (Δh) -Additional cost (Δc h ) NHS: Budget constrained health care system Displaced services -Health forgone -Resources released Cost-effectiveness threshold (k) - additional cost that would displace 1 unit of health

The role of the threshold? Cost Cost-effectiveness Threshold 20,000 per QALY Price > P* 60,000 30,000 per QALY Price = P* 40,000 20,000 per QALY Price < P* 20,000 10,000 per QALY 1 2 3 QALYs gained Net Health Benefit 1 QALY Net Health Benefit -1 QALY Claxton et al. British Medical Journal 2008;336:251-4.

Decision rules Δc h Δh < k Incremental cost effectiveness ratio Δh - Δc h k > 0 Net health benefits k.δh Δc h > 0 Net monetary benefits

More complex world: effects falling outside the NHS New technologies - Health gain (Δh) - Additional cost (Δc h ) NHS: Budget constrained health care system Net health impact Displaced services -Health forgone -Resources released - Non NHS direct costs/saving - Indirect costs/savings economy (e.g. production net of consumption) Δc c Consumption value of health (v) - Consumption considered equivalent to one unit of health

More general decision rule v. Δh - Δc h k - Δc c > 0 Accept technology if the net consumption value is positive v. Δh - Δc h k - Δc c > 0 If Δc c = 0 the decision will be same as standard decision rule regardless of v Δh - Δc h k - Δc c > 0 v Accept technology if net health gained in health sector is greater than the health equivalent of net consumption costs

What questions are posed? Measurement issues: Where do we get v from? Can we specify all the trade-offs? Do QALYs already include (some) consumption effects? How do we measure productivity effects? Displaced services can also have wider effects Long-term dynamic effects